Research Summaries

FDA ALERT
FDA ALERT
03/26/2026
Ashton L. Stahl
The FDA has approved Avlayah (tividenofusp alfa-eknm) for certain pediatric patients with Hunter syndrome, marking the first approval targeting the disease's neurologic complications and offering clinicians...
03/26/2026
Research Summary
Research Summary
03/09/2026
Kate Young
The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...
03/09/2026
Research Summary
Research Summary
02/09/2026
Anthony Calabro, MA
A phase 3 randomized trial evaluated the efficacy and safety of fremanezumab for preventive treatment of episodic migraine in children and adolescents, addressing a significant evidence gap in pediatric...
02/09/2026
Research Summary
Research Summary
01/21/2026
Ashton L. Stahl
A phase 4 TANDEM trial in the United States evaluated whether ubrogepant for acute migraine treatment can be safely added to atogepant and used daily for preventive therapy in adults with episodic migraine,...
01/21/2026
Research Summary
Research Summary
01/12/2026
Ashton L. Stahl
A large cross-sectional Italian study evaluated the prevalence of cognitive frailty and identified HIV-specific and clinical risk factors among adults 50 years or older living with HIV, highlighting the...
01/12/2026
Research Summary
Research Summary
11/26/2025
Kate Young
A large U.S. multicenter analysis compared early surgical evacuation versus initial conservative management for acute subdural hematoma in patients with traumatic brain injury. Results, published in JAMA...
11/26/2025
Research Summary
Research Summary
11/10/2025
Kate Young
A meta-analysis published in GeroScience evaluated data from 23 studies to determine the impact of adherence to the Mediterranean diet on the risk of cognitive impairment, dementia, and Alzheimer disease....
11/10/2025
Research Summary
Research Summary
10/08/2025
Kate Young
In a recent study, exposure to fine particulate matter (PM2.5) was associated with both more advanced Alzheimer disease neuropathologic change and greater dementia severity, with much of this link mediated...
10/08/2025
Research Summary
Research Summary
09/25/2025
Anthony Calabro, MA
In a phase 3 randomized controlled trial, escitalopram was not associated with significant improvement in agitation symptoms in patients with Alzheimer dementia and was linked to QT interval prolongation,...
09/25/2025
FDA Alert
FDA Alert
09/23/2025
Kate Young
The FDA initiated approval of leucovorin calcium tablets to treat cerebral folate deficiency (CFD) following a systematic analysis demonstrating promise in this patient population.
09/23/2025